Topiramate as an Adjunctive Treatment in Migraine Prophylaxis

Martínez, Héctor R.; Londoño, Orlando; Cantú‐Martínez, Leonel; Tarín, Luz del Carmen; Castillo, Carlos D.

doi:10.1046/j.1526-4610.2003.03209.x

Cited by 29 publications

(18 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Topiramate in the prophylaxis of migraine 3.1 Episodic migraine 3.1.1 Topiramate compared with placebo and in open-label trials The efficacy and safety of topiramate in the prophylaxis of episodic migraine with and without aura were initially evaluated in small studies and case series [33][34][35][36]. Later, three 26-week, large randomized controlled trials (RCTs) (two North American and one European), with similar design and inclusion criteria, were carried out [37][38][39].…”

Section: Pharmacokineticsmentioning

confidence: 99%

Clinical pharmacology of topiramate in migraine prevention

Ferrari

Tiraferri

Neri

et al. 2011

Expert Opinion on Drug Metabolism & Toxicology

View full text Add to dashboard Cite

Topiramate is an important option for the prophylaxis of migraine and is of proven efficacy and tolerability. It has also been studied in chronic migraine with encouraging results, even in patients with medication overuse. However, in migraine prevention its efficacy is comparable to the other first-line drugs and there are no published trials with a superiority design which can establish topiramate's role in the available therapeutic armamentarium.

show abstract

Section: Pharmacokineticsmentioning

confidence: 99%

Clinical pharmacology of topiramate in migraine prevention

Ferrari

Tiraferri

Neri

et al. 2011

Expert Opinion on Drug Metabolism & Toxicology

View full text Add to dashboard Cite

show abstract

“…This study demonstrated that over half the treated subjects responded to the combination treatment. A second open-label study investigated add-on treatment with topiramate in patients who responded inadequately to current prophylactic treatment, principally with propranolol or flunarizine (Martinez et al 2003). Again, headache frequency decreased after initiation of combination treatment.…”

Section: Prophylaxis Of Migrainementioning

confidence: 99%

Optimizing prophylactic treatment of migraine: Subtypes and patient matching

Dib¹

2008

TCRM

View full text Add to dashboard Cite

Advances in our understanding of the pathophysiology of migraine have resulted in important breakthroughs in treatment. For example, understanding of the role of serotonin in the cerebrovascular circulation has led to the development of triptans for the acute relief of migraine headaches, and the identifi cation of cortical spreading depression as an early central event associated wih migraine has brought renewed interest in antiepileptic drugs for migraine prophylaxis. However, migraine still remains inadequately treated. Indeed, it is apparent that migraine is not a single disease but rather a syndrome that can manifest itself in a variety of pathological conditions. The consequences of this may be that treatment needs to be matched to particular patients. Clinical research needs to be devoted to identifying which sort of patients benefi t best from which treatments, particularly in the fi eld of prophylaxis. We propose four patterns of precipitating factors (adrenergic, serotoninergic, menstrual, and muscular) which may be used to structure migraine prophylaxis. Finally, little is known about long-term outcome in treated migraine. It is possible that appropriate early prophylaxis may modify the long-term course of the disease and avoid late complications.

show abstract

“…Many studies have confirmed a significant therapeutic effect at the low dose of 100-200 mg/day, with the added advantage of better tolerability and lower discontinuation rates. Lower doses of topiramate are effective in migraine prophylaxis [50][51][52][85][86][87][88][89] and cluster headaches [90,91], partial-onset seizures [41,42,[92][93][94] and idiopathic generalized epilepsy [90].…”

Section: Tolerabilitymentioning

confidence: 99%

Topiramate for the treatment of epilepsy and other nervous system disorders

Passel

Arif

Hirsch

2006

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

Initially synthesized as an oral hypoglycemic agent, topiramate was approved for use as an anticonvulsant in 1996. Its broad spectrum efficacy in epilepsy, including as monotherapy and in children, is well established. Topiramate has also been used in the management of nonepileptic neurologic and psychiatric conditions, including migraine prophylaxis (with firmly established efficacy), obesity (with some evidence of long-term maintenance of weight loss), substance dependence, bipolar disorder and neuropathic pain, and it has been investigated as a possible neuroprotective agent. Paresthesias and cognitive side effects are the most common troublesome adverse effects. Recent trends towards lower doses may help achieve the best combination of efficacy and tolerability.

show abstract

Topiramate as an Adjunctive Treatment in Migraine Prophylaxis

Abstract: These results suggest that topiramate is efficacious and safe as an adjunctive treatment in patients with migraine whose prior response to prophylactic management has been less than satisfactory.

Cited by 29 publications

References 10 publications

Clinical pharmacology of topiramate in migraine prevention

Clinical pharmacology of topiramate in migraine prevention

Optimizing prophylactic treatment of migraine: Subtypes and patient matching

Topiramate for the treatment of epilepsy and other nervous system disorders

Contact Info

Product

Resources

About